Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

被引:655
作者
Sanz, Miguel A. [1 ]
Grimwade, David [2 ]
Tallman, Martin S. [3 ]
Lowenberg, Bob [4 ]
Fenaux, Pierre [5 ]
Estey, Elihu H. [6 ]
Naoe, Tomoki [7 ]
Lengfelder, Eva [8 ]
Buechner, Thomas [9 ]
Doehner, Hartmut [10 ]
Burnett, Alan K. [11 ]
Lo-Coco, Francesco [12 ]
机构
[1] Univ Hosp La Fe, Dept Hematol, Valencia 46009, Spain
[2] Kings Coll London, London WC2R 2LS, England
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[5] Hop Avicenne, Paris, France
[6] Seattle Canc Care Alliance, Seattle, WA USA
[7] Nagoya Univ, Nagoya, Aichi 4648601, Japan
[8] Univ Klinikum Mannheim, Heidelberg, Germany
[9] Univ Munster, Munster, Germany
[10] Univ Ulm, Ulm, Germany
[11] Cardiff Univ, Cardiff, S Glam, Wales
[12] Univ Roma Tor Vergata, Rome, Italy
关键词
TRANS-RETINOIC ACID; POLYMERASE-CHAIN-REACTION; MINIMAL-RESIDUAL-DISEASE; THERAPY-RELATED MYELODYSPLASIA; BONE-MARROW-TRANSPLANTATION; MONOCLONAL-ANTIBODY PG-M3; ACUTE MYELOID-LEUKEMIA; RT-PCR ANALYSIS; ARSENIC TRIOXIDE; REMISSION INDUCTION;
D O I
10.1182/blood-2008-04-150250
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The introduction of all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO) into the therapy of acute promyelocytic leukemia (APL) has revolutionized the management and outcome of this disease. Several treatment strategies using these agents, usually in combination with chemotherapy, but also without or with minimal use of cytotoxic agents, have provided excellent therapeutic results. Cure of APL patients, however, is also dependent on peculiar aspects related to the management and supportive measures that are crucial to counteract life-threatening complications associated with the disease biology and molecularly targeted treatment. The European LeukemiaNet recently appointed an international panel of experts to develop evidence-and expert opinion-based guidelines on the diagnosis and management of APL. Together with providing current indications on genetic diagnosis, modern risk-adapted front-line therapy and salvage treatment, the review contains specific recommendations for the identification and management of most important complications such as the bleeding disorder, APL differentiation syndrome, QT prolongation and other ATRA- and ATO-related toxicities, as well as for molecular assessment of response to treatment. Finally, the approach to special situations is also discussed, including management of APL in children, elderly patients, and pregnant women. (Blood. 2009; 113: 1875-1891)
引用
收藏
页码:1875 / 1891
页数:17
相关论文
共 148 条
[11]  
Avvisati G, 2003, BLOOD, V102, p142A
[12]   Effect of arsenic trioxide on QT interval in patients with advanced malignancies [J].
Barbey, JT ;
Pezzullo, JC ;
Soignet, SL .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) :3609-3615
[13]   Therapy-related acute promyelocytic leukemia [J].
Beaumont, M ;
Sanz, M ;
Carli, PM ;
Maloisel, F ;
Thomas, X ;
Detourmignies, L ;
Guerci, A ;
Gratecos, N ;
Rayon, C ;
Miguel, JS ;
Odriozola, J ;
Cahn, JY ;
Huguet, F ;
Vekhof, A ;
Stamatoulas, A ;
Dombret, H ;
Capote, F ;
Esteve, J ;
Stoppa, AM ;
Fenaux, P .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) :2123-2137
[14]  
Beaumont M, 2000, BLOOD, V96, p321A
[15]   PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[16]   PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) :620-625
[17]   ACUTE PROMYELOCYTIC LEUKEMIA - RESULTS OF TREATMENT BY DAUNORUBICIN [J].
BERNARD, J ;
WEIL, M ;
BOIRON, M ;
JACQUILLAT, C ;
FLANDRIN, G ;
GEMON, MF .
BLOOD, 1973, 41 (04) :489-496
[18]  
Breccia M, 2004, HAEMATOLOGICA, V89, P29
[19]   Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid:: Result of the randomized MRC trial [J].
Burnett, AK ;
Grimwade, D ;
Solomon, E ;
Wheatley, K ;
Goldstone, AH .
BLOOD, 1999, 93 (12) :4131-4143
[20]   Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukaemia with lower toxicity and resource usage: Preliminary results of the MRC AML15 trial [J].
Burnett, Alan K. ;
Hills, Robert K. ;
Grimwade, David ;
Goldstone, Anthony H. ;
Hunter, Ann ;
Milligan, Don ;
Prentice, Archie G. ;
Russell, Nigel H. ;
Wheatley, Keith .
BLOOD, 2007, 110 (11) :181A-181A